Jefferies Group LLC - SAREPTA THERAPEUTICS INC ownership

SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 258 filers reported holding SAREPTA THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.

Quarter-by-quarter ownership
Jefferies Group LLC ownership history of SAREPTA THERAPEUTICS INC
ValueSharesWeighting
Q3 2022$26,322,669
+51.6%
238,128
+2.8%
0.22%
+51.7%
Q2 2022$17,362,160
-1.6%
231,619
+2.5%
0.14%
+30.6%
Q1 2022$17,651,370
-41.2%
225,952
-32.3%
0.11%
-36.9%
Q4 2021$30,041,671
+1616.8%
333,611
+1382.1%
0.18%
+1500.0%
Q2 2021$1,749,850
-7.0%
22,509
-10.8%
0.01%
-31.2%
Q1 2021$1,880,616
-72.8%
25,233
-37.7%
0.02%
-70.9%
Q4 2020$6,903,481
+102.3%
40,492
+66.6%
0.06%
+44.7%
Q3 2020$3,413,000
-13.0%
24,309
-0.7%
0.04%
-17.4%
Q2 2020$3,924,000
+49.6%
24,472
-8.7%
0.05%
+58.6%
Q1 2020$2,623,000
-74.5%
26,810
-66.4%
0.03%
-63.8%
Q4 2019$10,300,000
-69.1%
79,822
-82.0%
0.08%
-69.1%
Q3 2019$33,370,000
-3.6%
443,054
+94.4%
0.26%
+2.4%
Q2 2019$34,633,000
-0.0%
227,917
-21.6%
0.25%
-11.5%
Q1 2019$34,642,000
+398.3%
290,645
+356.3%
0.29%
+410.7%
Q4 2018$6,952,000
-20.1%
63,697
+18.3%
0.06%
-1.8%
Q3 2018$8,699,000
-47.5%
53,859
-57.0%
0.06%
-38.7%
Q2 2018$16,555,000
+219.9%
125,250
+34.7%
0.09%
+287.5%
Q4 2017$5,175,000
+115.6%
93,000
+75.8%
0.02%
+50.0%
Q3 2017$2,400,000
-0.7%
52,900
-26.2%
0.02%0.0%
Q2 2017$2,417,000
-74.4%
71,700
-77.5%
0.02%
-77.1%
Q1 2017$9,427,000
-85.4%
318,500
-86.5%
0.07%
-80.6%
Q4 2016$64,527,000
-80.1%
2,352,442
-55.5%
0.36%
-78.4%
Q3 2016$324,982,000
+171.9%
5,292,014
-15.6%
1.68%
+209.0%
Q2 2016$119,507,000
+144.7%
6,266,729
+150.4%
0.54%
+92.9%
Q1 2016$48,848,000
+513.1%
2,502,479
+1111.9%
0.28%
+524.4%
Q4 2015$7,967,000
-21.3%
206,500
-34.5%
0.04%
-22.4%
Q3 2015$10,117,000
+74.0%
315,043
+64.9%
0.06%
+93.3%
Q2 2015$5,815,000
+938.4%
191,100
+352.8%
0.03%
+900.0%
Q1 2015$560,000
-94.3%
42,203
-93.8%
0.00%
-94.8%
Q4 2014$9,798,000
-28.2%
677,129
+4.6%
0.06%
-38.3%
Q3 2014$13,654,000
-52.1%
647,106
-32.3%
0.09%
-61.0%
Q2 2014$28,483,000
-20.1%
956,110
-35.5%
0.24%
-30.5%
Q1 2014$35,636,000
-23.0%
1,482,999
-34.7%
0.35%
+17.6%
Q4 2013$46,256,000
-45.8%
2,270,762
+25.6%
0.30%
-64.7%
Q3 2013$85,362,000
+71.4%
1,807,371
+38.0%
0.84%
+56.4%
Q2 2013$49,798,0001,309,4390.53%
Other shareholders
SAREPTA THERAPEUTICS INC shareholders Q4 2017
NameSharesValueWeighting ↓
Perceptive Advisors 2,878,979$69,182,0007.27%
Eventide Asset Management 259,100$6,226,0000.97%
GLADE BROOK CAPITAL PARTNERS LLC 251,000$6,032,0000.93%
IMS Capital Management 32,215$774,0000.91%
Perceptive Advisors 350,000$8,413,0000.88%
Benchmark Capital Advisors 34,900$839,0000.58%
BECK CAPITAL MANAGEMENT, LLC 24,744$636,0000.49%
SABBY MANAGEMENT, LLC 352,100$8,461,0000.47%
Hatteras Alternative Mutual Funds, LLC 39,404$947,0000.46%
Potomac Capital Management, Inc. 22,100$531,0000.45%
View complete list of SAREPTA THERAPEUTICS INC shareholders